Endometrial Cancer: From Molecular Pathology to Novel Therapeutic Approaches

Dear Colleagues,

Endometrial Cancer (EC) is the most frequent cancer in the female genital tract that occurs in reproductive and postmenopausal women with an increasing incidence in women under 40 years of age. EC patients have a good prognosis at early stages, but the prognosis remains poor for recurrent or metastatic EC.

Current research demonstrates that the interactive crosstalk between infiltrating immune and stromal cells impacts the biological behavior of EC, suggesting that a unique immune-related tumor microenvironment (TME) may predict patients’ prognosis and guide immune checkpoint blockade therapies in EC. 

Thus, blocking cancer-promoting signals from the TME or re-educating stromal cells may be an effective strategy to impair metastatic progression and develop novel therapies.

Substantial research establishing an association of immune risk score with patients’ molecular features to predict EC progression, response, and recurrence, is needed.

This Special Issue aims to provide an update about the current cutting-edge molecular and pathological aspects of the EC that may lead to the discovery of novel treatment options for patients.

No guidelines to appropriately manage these patients exist, thus new potential biomarkers for EC screening are required.

We welcome original research or state-of-the-art reviews proposing novel insights in basic, translational, and clinical research on EC. Research areas may include (but are not limited to) the discovery of new therapeutic strategies, therapeutic resistance, and novel immunotherapeutic approaches. A particular area of interest is the discovery of molecular/cellular mechanisms and dynamic interactions within the TME and host–tumor interface that would pave the way for novel immunotherapeutic approaches.

We also aim to collect research articles/reviews discussing new diagnostic or prognostic tools for EC detection and tracing (omics-derived biomarkers, circulating biomarkers, microbiome, imaging).

Prof. Dr. Denisa Baci
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• endometrial cancer
• tumor microenvironment
• immunotherapy
• innate immunity
• extracellular vesicles
• noncoding RNAs
• tumor angiogenesis
• cancer biomarkers
• drug resistance